Didier Scherrer
Chief Tech/Sci/R&D Officer at ABIVAX
Net worth: 564 574 $ as of 30/04/2024
Network origin in Didier Scherrer first degree
Entity | Entity type | Industry | |
---|---|---|---|
14
| Public Company | Pharmaceuticals: Other | 14 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.
5
| Subsidiary | Information Technology Services | 5 |
AstraZeneca SAS
AstraZeneca SAS Pharmaceuticals: MajorHealth Technology AstraZeneca SAS researches, develops, produces, and commercializes pharmaceutical products. It offers solutions in different domains such as cardio-vascular, metabolism, oncology, respiratory, and inflammatory diseases. The company was founded on April 21, 1955 and is headquartered in Courbevoie, France.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Didier Scherrer via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Chief Administrative Officer | |
GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal | |
ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Public Communications Contact Corporate Officer/Principal | |
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Ferris State University (Michigan) | College/University | Undergraduate Degree | |
The Pennsylvania State University | College/University | Undergraduate Degree Masters Business Admin | |
University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
The University of California, San Francisco | College/University | Corporate Officer/Principal | |
INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Public Communications Contact | |
ESSEC Business School | College/University | Corporate Officer/Principal | |
ESCP Europe Campus Paris | College/University | Corporate Officer/Principal | |
France Biotech Association
France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Miscellaneous Commercial Services | Founder Corporate Officer/Principal | |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Juvaris BioTherapeutics, Inc.
Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Biotechnology | Director/Board Member | |
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH. | Hospital/Nursing Management | Director of Finance/CFO | |
Leem | Founder | ||
Tc Land Expression SA
Tc Land Expression SA Miscellaneous Commercial ServicesCommercial Services Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France. | Miscellaneous Commercial Services | Director/Board Member | |
PX Therapeutics SA
PX Therapeutics SA Miscellaneous Commercial ServicesCommercial Services PX Therapeutics SA manufactures and develops recombinant proteins and monoclonal antibodies. Its services include protein engineering, optimization of drug candidates, humanization of antibodies, and production and release of GMP batches for clinical studies. The firm specializes in the field of in-vivo and in-vitro diagnostics, industrial enzymes, and ancillary products. The company was founded by Tristan Rousselle and Nicolas Mouz in November 2000 and is headquartered in Grenoble, France. | Miscellaneous Commercial Services | Director/Board Member | |
PHARNEXT SCA | Biotechnology | Founder Director/Board Member | |
The San Francisco Aids Foundation
The San Francisco Aids Foundation Miscellaneous Commercial ServicesCommercial Services The San Francisco Aids Foundation provides education, advocacy, and direct services for HIV prevention and care. The private company is based in San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Chairman | |
KARA THER | Pharmaceuticals: Major | Director of Finance/CFO | |
The Innovative Medicines Initiative
The Innovative Medicines Initiative Drugstore ChainsRetail Trade The Innovative Medicines Initiative is a public-private partnership that aims to accelerate the development of better and safer medicines for patients. The private company is based in Brussels, Belgium and has subsidiaries in Sweden. The Programme Office, led by the Executive Director, manages the day-to-day operations of the initiative. The initiative recognizes the importance of communication and provides accessible tools generated by their projects to help scientists in their research efforts. The Belgian company was founded by J. Kenneth Charles Knowles. | Drugstore Chains | Chairman | |
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Biotechnology | Chairman | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
GALMED PHARMACEUTICALS LTD. | Pharmaceuticals: Major | Director/Board Member | |
SCPHARMACEUTICALS INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Société des Membres de la Légion d'Honneur | Director/Board Member | ||
TOBIRA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member | |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Biotechnology | Chief Executive Officer | |
PharmaLex GmbH
PharmaLex GmbH Packaged SoftwareTechnology Services PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany. | Packaged Software | Chief Operating Officer | |
East Bay AIDS Center | Founder | ||
CINCOR PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member Human Resources Officer | |
GALENICA AG | Medical Distributors | Director/Board Member | |
G5 Santé | Chairman | ||
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Biotechnology | Director of Finance/CFO | |
CONTINEUM THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Statistics
International
United States | 28 |
France | 12 |
Belgium | 4 |
Switzerland | 3 |
Luxembourg | 2 |
Sectoral
Health Technology | 26 |
Consumer Services | 8 |
Commercial Services | 6 |
Finance | 2 |
Health Services | 2 |
Operational
Director/Board Member | 117 |
Chairman | 40 |
Corporate Officer/Principal | 39 |
Founder | 26 |
Independent Dir/Board Member | 19 |
Most connected contacts
Insiders | |
---|---|
Philippe Pouletty | 51 |
Jon Saxe | 43 |
Marc M. P. de Garidel | 31 |
Carol Brosgart | 25 |
June Lee | 14 |
Troy Ignelzi | 12 |
Jeffrey E. Devers | 10 |
Mike Koo | 9 |
Pierre Courteille | 8 |
Kinam Hong | 8 |
Alan S. Blazei | 8 |
J. Michael French | 7 |
Didier Blondel | 6 |
Corinna Zur Bonsen-Thomas | 5 |
Jean-Pierre Bracquemart | 4 |
- Stock Market
- Insiders
- Didier Scherrer
- Company connections